Comparison of Telavancin and Vancomycin for Complicated S... | NCT00091819

Status Module

Oversight Module

Design Module

Interventional Study Design

Biospecimen

No data available

No data is available for this block.

Label	Type	Description	Intervention Names
Telavancin	Experimental		Drug: Telavancin
Vancomycin	Active Comparator		Drug: Vancomycin

Name	Type	Description	Arm Group Labels	Other Names
Telavancin	Drug	Telavancin 10 mg/kg/day, IV for up to 14 days.	Telavancin

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Clinical Response	The Clinical Response for each patient was determined by the investigator by assessing a patient's clinical signs and symptoms at the specified evaluation compared with the Baseline evaluation. Cure: resolution of signs and symptoms associated with the skin infection present at study admission such that no further antibiotic therapy was necessary; Not Cured: inadequate response to study therapy; Indeterminate: unable to determine outcome.	7-14 days following end of antibiotic treatment

Eligibility Module

Name	Affiliation	Role
G. Ralph Corey, MD	Duke University	Principal Investigator

Facility	Status	City	State	ZIP	Country	Contacts
Paradise Valley Hospital, 2400 E. 4th Street		National City	California	91950	United States

References Module

Citations

PubMed Identifier	Type	Citation	Retractions
18444791	Result	Stryjewski ME, Graham DR, Wilson SE, O'Riordan W, Young D, Lentnek A, Ross DP, Fowler VG, Hopkins A, Friedland HD, Barriere SL, Kitt MM, Corey GR; Assessment of Telavancin in Complicated Skin and Skin-Structure Infections Study. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis. 2008 Jun 1;46(11):1683-93. doi: 10.1086/587896.
19095213

Results Section

Participant Flow Module

Arm/Group Information

ID	Title	Description
FG000	Telavancin	Patients with complicated Gram-positive skin and skin structure infections (primarily due to MRSA) were randomized to receive telavancin 10 mg/kg IV once daily. The maximum allowable treatment period was 14 days.
FG001	Vancomycin

Baseline Characteristics Module

Outcome Measures Module

Adverse Events Module

More Info Module

Arm/Group Information

ID	Title	Description
BG000	Telavancin	Patients with complicated Gram-positive skin and skin structure infections (primarily due to MRSA) were randomized to receive telavancin 10 mg/kg IV once daily. The maximum allowable treatment period was 14 days.
BG001	Vancomycin	Patients with complicated Gram-positive skin and skin structure infections (primarily due to MRSA) were randomized to receive vancomycin 1 Gram every 12 hours. The maximum allowable treatment period was 14 days.
BG002	Total	Total of all reporting groups

Units	Counts
Participants	BG000426 BG001429 BG002855

Baseline Measures

Title

Description

Population Description

Parameter Type

Dispersion Type

Unit of Measure

Calculate Percentage

Denominator Units Selected

Denominators

Classes

Age, Categorical

Count of Participants

Participants

Title

Denominators

Categories

Title	Measurements
<=18 years	BG0000 BG0010 BG0020
Between 18 and 65 years

Age, Continuous

Mean

Standard Deviation

years

Title

Denominators

Categories

Title	Measurements
	BG00049± 17.3 BG00148± 16.1 BG002

Sex: Female, Male

Count of Participants

Participants

Title

Denominators

Categories

Title	Measurements
Female	BG000196 BG001181 BG002

Ethnicity (NIH/OMB)

Count of Participants

Participants

Title

Denominators

Categories

Title	Measurements
Hispanic or Latino	BG000114 BG00197 BG002

Race (NIH/OMB)

Patients could indicate more than one racial category.

Count of Participants

Participants

Title

Denominators

Categories

Title	Measurements
American Indian or Alaska Native	BG0003 BG0012 BG002

Region of Enrollment

Number

participants

Title

Denominators

Categories

United States

Title	Measurements
	BG000306 BG001316 BG002

Diabetes Status

Number

Participants

Title

Denominators

Categories

Diabetic

Title	Measurements
	BG00094 BG00198 BG002

Type

Title

Description

Population Description

Reporting Status

Anticipated Posting Date

Parameter Type

Dispersion Type

Unit of Measure

Calculate Percentage

Time Frame

Units Analyzed

Denominator Units Selected

Arm/Group Information

Denominators

Classes

Analyses

Primary

Clinical Response

The Clinical Response for each patient was determined by the investigator by assessing a patient's clinical signs and symptoms at the specified evaluation compared with the Baseline evaluation. Cure: resolution of signs and symptoms associated with the skin infection present at study admission such that no further antibiotic therapy was necessary; Not Cured: inadequate response to study therapy; Indeterminate: unable to determine outcome.

Data for the all-treated (AT) population are presented. the AT and clinically evaluable (CE) populations were considered co-primary.

Posted

Number

participants

7-14 days following end of antibiotic treatment

ID	Title	Description
OG000	Telavancin	Patients with complicated Gram-positive skin and skin structure infections (primarily due to MRSA) were randomized to receive telavancin 10 mg/kg IV once daily. The maximum allowable treatment period was 14 days.
OG001	Vancomycin	Patients with complicated Gram-positive skin and skin structure infections (primarily due to MRSA) were randomized to receive vancomycin 1 Gram every 12 hours. The maximum allowable treatment period was 14 days.

Units	Counts
Participants	OG000426 OG001429

Title

Denominators

Categories

Cure

Title	Measurements
	OG000323 OG001321

Not cured

Title	Measurements
	OG000

Group IDs	Group Description	Statistical Method	Statistical Comment	P-Value	P-Value Comment	Parameter Type	Parameter Value	Dispersion Type	Dispersion Value	Confidence Interval Sides	Confidence Interval %	CI Lower Limit	CI Upper Limit	CI Lower Limit Comment	CI Upper Limit Comment	Estimate Comment	Tested Non-Inferiority	Non-Inferiority Type	Non-Inferiority Comment	Other Analysis Description
OG000 OG001					p-values were not calculated in deference to confidence intervals.	Risk Difference (RD)	1.0				95	-4.8	6.8			Statistical analysis applies to "cure"		Non-Inferiority or Equivalence	Non-inferiority margin of 10% was specified based on historical regulatory precedent.

Arm/Groups

ID	Title	Description	Deaths (Affected)	Deaths (At Risk)	Serious Events (Affected)	Serious Events (At Risk)	Other Events (Affected)	Other Events (At Risk)
EG000	Telavancin	Patients with complicated Gram-positive skin and skin structure infections (primarily due to MRSA) were randomized to receive telavancin 10 mg/kg IV once daily. The maximum allowable treatment period was 14 days.			31	426	358	426
EG001	Vancomycin	Patients with complicated Gram-positive skin and skin structure infections (primarily due to MRSA) were randomized to receive vancomycin 1 Gram every 12 hours. The maximum allowable treatment period was 14 days.			27	429	335	429

Serious Adverse Events

Term	Organ System	Assessment Type	Statistical Information
Renal Failure Acute	Renal and urinary disorders	Systematic Assessment	EG0001 affected426 at risk EG0010 affected429 at risk
Myocardial Infarction	Cardiac disorders	Systematic Assessment	EG0002 affected426 at risk EG0010 affected429 at risk
Blood creatinine increased	Investigations	Systematic Assessment	EG0000 affected426 at risk EG0012 affected429 at risk
Drug Hypersensitivity	Immune system disorders	Systematic Assessment	EG0001 affected426 at risk EG0011 affected429 at risk
Hypotension	Vascular disorders	Systematic Assessment	EG0001 affected426 at risk EG0011 affected429 at risk
Mental Status Changes	Psychiatric disorders	Systematic Assessment	EG0001 affected426 at risk EG0010 affected429 at risk
Renal Insufficiency	Renal and urinary disorders	Systematic Assessment	EG0001 affected426 at risk EG0010 affected429 at risk
Deep Vein Thrombosis	Vascular disorders	Systematic Assessment	EG0002 affected426 at risk EG0010 affected429 at risk
Osteomyelitis	Infections and infestations	Systematic Assessment	EG0001 affected426 at risk EG0010 affected429 at risk
Peripheral Occlusive Disease	Vascular disorders	Systematic Assessment	EG0001 affected426 at risk EG0010 affected429 at risk
Pneumonia	Infections and infestations	Systematic Assessment	EG0000 affected426 at risk EG0011 affected429 at risk
Pulmonary Embolism	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0002 affected426 at risk EG0012 affected429 at risk
Rash	Skin and subcutaneous tissue disorders	Systematic Assessment	EG0001 affected426 at risk EG0010 affected429 at risk
Renal Impairment	Renal and urinary disorders	Systematic Assessment	EG0002 affected426 at risk EG0010 affected429 at risk
Respiratory Distress	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0002 affected426 at risk EG0012 affected429 at risk
Angina Pectoris	Cardiac disorders	Systematic Assessment	EG0001 affected426 at risk EG0010 affected429 at risk
Ankle Fracture	Injury, poisoning and procedural complications	Systematic Assessment	EG0001 affected426 at risk EG0010 affected429 at risk
Atrial fibrillation	Cardiac disorders	Systematic Assessment	EG0000 affected426 at risk EG0012 affected429 at risk
Bradycardia	Cardiac disorders	Systematic Assessment	EG0001 affected426 at risk EG0011 affected429 at risk
Calculus Bladder	Renal and urinary disorders	Systematic Assessment	EG0001 affected426 at risk EG0010 affected429 at risk
Cardio-Respiratory Arrest	Cardiac disorders	Systematic Assessment	EG0000 affected426 at risk EG0011 affected429 at risk
Cerebrovascular Accident	Nervous system disorders	Systematic Assessment	EG0001 affected426 at risk EG0010 affected429 at risk
Chest Discomfort	General disorders	Systematic Assessment	EG0001 affected426 at risk EG0010 affected429 at risk
Chronic Obstructive Airways Disease Exacerbated	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0001 affected426 at risk EG0010 affected429 at risk
Dyspnoea	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0000 affected426 at risk EG0011 affected429 at risk
Hypersensitivity	Immune system disorders	Systematic Assessment	EG0000 affected426 at risk EG0011 affected429 at risk
Injection Site Cellulitis	General disorders	Systematic Assessment	EG0001 affected426 at risk EG0010 affected429 at risk
International Normalised Ratio Increased	Investigations	Systematic Assessment	EG0001 affected426 at risk EG0010 affected429 at risk
Myocardial Ischaemia	Cardiac disorders	Systematic Assessment	EG0001 affected426 at risk EG0010 affected429 at risk
Ovarian Cancer	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0001 affected426 at risk EG0010 affected429 at risk
Pulmonary Congestion	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0001 affected426 at risk EG0010 affected429 at risk
Respiratory Failure	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0001 affected426 at risk EG0013 affected429 at risk
Schizophrenia, Paranoid Type	Psychiatric disorders	Systematic Assessment	EG0001 affected426 at risk EG0010 affected429 at risk
Systemic Inflammatory Response Syndrome	General disorders	Systematic Assessment	EG0001 affected426 at risk EG0010 affected429 at risk
Thrombocytopenia	Blood and lymphatic system disorders	Systematic Assessment	EG0000 affected426 at risk EG0011 affected429 at risk
Urinary Tract Infection	Renal and urinary disorders	Systematic Assessment	EG0000 affected426 at risk EG0011 affected429 at risk
Varicose Vein Ruptured	Vascular disorders	Systematic Assessment	EG0001 affected426 at risk EG0010 affected429 at risk
Ventricular Arrhythmia	Cardiac disorders	Systematic Assessment	EG0001 affected426 at risk EG0010 affected429 at risk
Abdominal Pain	Gastrointestinal disorders	Systematic Assessment	EG0000 affected426 at risk EG0012 affected429 at risk
Bacteraemia	Infections and infestations	Systematic Assessment	EG0000 affected426 at risk EG0011 affected429 at risk
Bronchitis	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0000 affected426 at risk EG0011 affected429 at risk
Cardiac failure	Cardiac disorders	Systematic Assessment	EG0000 affected426 at risk EG0011 affected429 at risk
Cardiac failure congestive	Cardiac disorders	Systematic Assessment	EG0000 affected426 at risk EG0011 affected429 at risk
Cellulitis	Infections and infestations	Systematic Assessment	EG0000 affected426 at risk EG0011 affected429 at risk
Coma Hepatic	Nervous system disorders	Systematic Assessment	EG0000 affected426 at risk EG0011 affected429 at risk
Gastroenteritis	Infections and infestations	Systematic Assessment	EG0000 affected426 at risk EG0011 affected429 at risk
Hyperglycemia	Metabolism and nutrition disorders	Systematic Assessment	EG0000 affected426 at risk EG0011 affected429 at risk
Leukopenia	Blood and lymphatic system disorders	Systematic Assessment	EG0000 affected426 at risk EG0011 affected429 at risk
Non-Cardiac Chest Pain	General disorders	Systematic Assessment	EG0000 affected426 at risk EG0011 affected429 at risk
Ovarian Cyst	Reproductive system and breast disorders	Systematic Assessment	EG0000 affected426 at risk EG0011 affected429 at risk
Pelvic Infection	Infections and infestations	Systematic Assessment	EG0000 affected426 at risk EG0011 affected429 at risk
Post-Procedural Haemorrhage	Injury, poisoning and procedural complications	Systematic Assessment	EG0000 affected426 at risk EG0011 affected429 at risk
Procedural Hypotension	Injury, poisoning and procedural complications	Systematic Assessment	EG0000 affected426 at risk EG0011 affected429 at risk
Pyrexia	General disorders	Systematic Assessment	EG0000 affected426 at risk EG0011 affected429 at risk
Renal Vessel Disorder	Renal and urinary disorders	Systematic Assessment	EG0000 affected426 at risk EG0011 affected429 at risk
Upper Gastrointestinal Haemorrhage	Gastrointestinal disorders	Systematic Assessment	EG0000 affected426 at risk EG0011 affected429 at risk
White Blood Cell Count Increased	Blood and lymphatic system disorders	Systematic Assessment	EG0000 affected426 at risk EG0011 affected429 at risk

Other Adverse Events

Term	Organ System	Assessment Type	Statistical Information
Anemia	Blood and lymphatic system disorders	Systematic Assessment	EG00012 affected426 at risk EG0018 affected429 at risk
Angina Pectoris	Cardiac disorders	Systematic Assessment	EG0005 affected426 at risk EG0011 affected429 at risk
Bradycardia	Cardiac disorders	Systematic Assessment	EG0002 affected426 at risk EG0015 affected429 at risk
Cardiac failure congestive	Cardiac disorders	Systematic Assessment	EG0005 affected426 at risk EG0012 affected429 at risk
Palpitations	Cardiac disorders	Systematic Assessment	EG0006 affected426 at risk EG0013 affected429 at risk
Vision blurred	Eye disorders	Systematic Assessment	EG0005 affected426 at risk EG0013 affected429 at risk
Abdominal Distension	Gastrointestinal disorders	Systematic Assessment	EG0005 affected426 at risk EG0014 affected429 at risk
Abdominal pain	Gastrointestinal disorders	Systematic Assessment	EG00011 affected426 at risk EG00117 affected429 at risk
Abdominal pain upper	Gastrointestinal disorders	Systematic Assessment	EG0005 affected426 at risk EG0018 affected429 at risk
Constipation	Gastrointestinal disorders	Systematic Assessment	EG00061 affected426 at risk EG00137 affected429 at risk
Diarrhoea	Gastrointestinal disorders	Systematic Assessment	EG00031 affected426 at risk EG00141 affected429 at risk
Dry Mouth	Gastrointestinal disorders	Systematic Assessment	EG00011 affected426 at risk EG00115 affected429 at risk
Dyspepsia	Gastrointestinal disorders	Systematic Assessment	EG00014 affected426 at risk EG00116 affected429 at risk
Loose stools	Gastrointestinal disorders	Systematic Assessment	EG0005 affected426 at risk EG0017 affected429 at risk
Nausea	Gastrointestinal disorders	Systematic Assessment	EG000128 affected426 at risk EG00195 affected429 at risk
Vomiting	Gastrointestinal disorders	Systematic Assessment	EG00078 affected426 at risk EG00150 affected429 at risk
Asthenia	General disorders	Systematic Assessment	EG0008 affected426 at risk EG0019 affected429 at risk
Fatigue	General disorders	Systematic Assessment	EG00019 affected426 at risk EG00121 affected429 at risk
Infusion site erythema	General disorders	Systematic Assessment	EG0007 affected426 at risk EG0019 affected429 at risk
Infusion site pain	General disorders	Systematic Assessment	EG00021 affected426 at risk EG00121 affected429 at risk
Infusion site phlebitis	General disorders	Systematic Assessment	EG0006 affected426 at risk EG0017 affected429 at risk
Infusion site pruritis	General disorders	Systematic Assessment	EG0005 affected426 at risk EG0019 affected429 at risk
Infusion site reaction	General disorders	Systematic Assessment	EG0007 affected426 at risk EG0017 affected429 at risk
Lethargy	General disorders	Systematic Assessment	EG0006 affected426 at risk EG0011 affected429 at risk
Non-Cardiac Chest Pain	General disorders	Systematic Assessment	EG00012 affected426 at risk EG0017 affected429 at risk
Oedema Peripheral	General disorders	Systematic Assessment	EG0008 affected426 at risk EG00111 affected429 at risk
Pain	General disorders	Systematic Assessment	EG0004 affected426 at risk EG0017 affected429 at risk
Pyrexia	General disorders	Systematic Assessment	EG0009 affected426 at risk EG00110 affected429 at risk
Rigors	General disorders	Systematic Assessment	EG00022 affected426 at risk EG00114 affected429 at risk
Fungal Infection	Infections and infestations	Systematic Assessment	EG0005 affected426 at risk EG0012 affected429 at risk
Osteomyelitis	Infections and infestations	Systematic Assessment	EG0005 affected426 at risk EG0014 affected429 at risk
Pneumonia	Infections and infestations	Systematic Assessment	EG0005 affected426 at risk EG0011 affected429 at risk
Urinary Tract Infection	Infections and infestations	Systematic Assessment	EG0006 affected426 at risk EG0014 affected429 at risk
Vaginal candidiasis	Infections and infestations	Systematic Assessment	EG0005 affected426 at risk EG0010 affected429 at risk
Vaginal mycosis	Infections and infestations	Systematic Assessment	EG0005 affected426 at risk EG0016 affected429 at risk
Anorexia	Metabolism and nutrition disorders	Systematic Assessment	EG00010 affected426 at risk EG00110 affected429 at risk
Decreased appetite	Metabolism and nutrition disorders	Systematic Assessment	EG00013 affected426 at risk EG00117 affected429 at risk
Hypoglycaemia	Metabolism and nutrition disorders	Systematic Assessment	EG00011 affected426 at risk EG0018 affected429 at risk
Hypokalemia	Metabolism and nutrition disorders	Systematic Assessment	EG0001 affected426 at risk EG0017 affected429 at risk
Hypomagnesaemia	Metabolism and nutrition disorders	Systematic Assessment	EG0001 affected426 at risk EG0016 affected429 at risk
Arthralgia	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG00012 affected426 at risk EG0018 affected429 at risk
Back Pain	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG00014 affected426 at risk EG0018 affected429 at risk
Muscle Cramp	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0005 affected426 at risk EG0016 affected429 at risk
Pain in Extremity	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0008 affected426 at risk EG0017 affected429 at risk
Dizziness	Nervous system disorders	Systematic Assessment	EG00027 affected426 at risk EG00135 affected429 at risk
Dysgeusia	Nervous system disorders	Systematic Assessment	EG000156 affected426 at risk EG00131 affected429 at risk
Headache	Nervous system disorders	Systematic Assessment	EG00082 affected426 at risk EG00169 affected429 at risk
Hypoaesthesia	Nervous system disorders	Systematic Assessment	EG0003 affected426 at risk EG0015 affected429 at risk
Paresthesia	Nervous system disorders	Systematic Assessment	EG0003 affected426 at risk EG0015 affected429 at risk
Agitation	Psychiatric disorders	Systematic Assessment	EG0004 affected426 at risk EG0016 affected429 at risk
Anxiety	Psychiatric disorders	Systematic Assessment	EG00018 affected426 at risk EG00114 affected429 at risk
Confusional State	Psychiatric disorders	Systematic Assessment	EG0007 affected426 at risk EG0014 affected429 at risk
Insomnia	Psychiatric disorders	Systematic Assessment	EG00071 affected426 at risk EG00153 affected429 at risk
Restlessness	Psychiatric disorders	Systematic Assessment	EG0004 affected426 at risk EG0016 affected429 at risk
Dysuria	Renal and urinary disorders	Systematic Assessment	EG0007 affected426 at risk EG0015 affected429 at risk
Haematuria	Renal and urinary disorders	Systematic Assessment	EG0006 affected426 at risk EG0010 affected429 at risk
Renal Insufficiency	Renal and urinary disorders	Systematic Assessment	EG0005 affected426 at risk EG0011 affected429 at risk
Urinary Incontinence	Renal and urinary disorders	Systematic Assessment	EG0006 affected426 at risk EG0013 affected429 at risk
Urinary Abnormality	Renal and urinary disorders	Systematic Assessment	EG00069 affected426 at risk EG0018 affected429 at risk
Genital Pruritis Female	Reproductive system and breast disorders	Systematic Assessment	EG0008 affected426 at risk EG0016 affected429 at risk
Cough	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG00012 affected426 at risk EG00113 affected429 at risk
Dyspnoea	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG00010 affected426 at risk EG0017 affected429 at risk
Pharyngolaryngeal Pain	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG00015 affected426 at risk EG00113 affected429 at risk
Productive Cough	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0001 affected426 at risk EG0015 affected429 at risk
Dry Skin	Skin and subcutaneous tissue disorders	Systematic Assessment	EG0006 affected426 at risk EG00111 affected429 at risk
Erythema	Skin and subcutaneous tissue disorders	Systematic Assessment	EG0006 affected426 at risk EG00113 affected429 at risk
Exanthem	Skin and subcutaneous tissue disorders	Systematic Assessment	EG0007 affected426 at risk EG0014 affected429 at risk
Hyperhidrosis	Skin and subcutaneous tissue disorders	Systematic Assessment	EG00010 affected426 at risk EG0019 affected429 at risk
Pruritis	Skin and subcutaneous tissue disorders	Systematic Assessment	EG00025 affected426 at risk EG00158 affected429 at risk
Pruritis generalized	Skin and subcutaneous tissue disorders	Systematic Assessment	EG00019 affected426 at risk EG00140 affected429 at risk
Rash	Skin and subcutaneous tissue disorders	Systematic Assessment	EG00017 affected426 at risk EG00123 affected429 at risk
Rash generalized	Skin and subcutaneous tissue disorders	Systematic Assessment	EG0001 affected426 at risk EG0019 affected429 at risk
Hot Flush	Vascular disorders	Systematic Assessment	EG0002 affected426 at risk EG0017 affected429 at risk
Hypertension	Vascular disorders	Systematic Assessment	EG0006 affected426 at risk EG0017 affected429 at risk
Hypotension	Vascular disorders	Systematic Assessment	EG00012 affected426 at risk EG0017 affected429 at risk

ID	Term
D013207	Staphylococcal Skin Infections
D013203	Staphylococcal Infections

ID	Term
D016908	Gram-Positive Bacterial Infections
D001424	Bacterial Infections
D001423	Bacterial Infections and Mycoses
D007239	Infections
D017192	Skin Diseases, Bacterial
D012874	Skin Diseases, Infectious
D012871	Skin Diseases
D017437	Skin and Connective Tissue Diseases

ID	Term
D006020	Glycopeptides
D006001	Glycoconjugates
D002241	Carbohydrates
D010455	Peptides
D000602	Amino Acids, Peptides, and Proteins